| Symbol | TSX : AMB |
|---|---|
| Last trade | 0.07 |
| Volume | 40,475 |
| As of | 2009-01-05 15:35 EST |
| Note: Quotes are delayed. For informational purposes only. |
|
Corporate governance
Ambrilia Biopharma is committed to follow and maintain high standards of Corporate Governance. The Board of Directors of Ambrilia believes that good governance practices protect long-term shareholder value and ensures that the Company conducts its activities and operations with integrity and in an ethical manner, geared towards shareholder’s best interest. The Company aligns with the recommendations of the Toronto Stock Exchange’s Corporate Governance Guidelines as detailed in its Statement of Corporate Governance Practice (contained in the Management’s Proxy Circular).
Additional information, including Ambrilia’s financial reports and other regulatory filings can be found in the Investor Section of this web site under Financial Reports as well as on the System for Electronic Documents Analysis and Retrieval (SEDAR) at www.sedar.com
Board of Directors
Philippe Calais, Ph.D., Pharm. - President and Chief Executive Officer, Ambrilia
Bonabes de Rougé, M.D. - Senior Executive Vice-President and Chief Scientific Officer, Ambrilia
François Lombard, Ph.D. - Chief Executive Officer, Turenne Capital Partenaires (France)
Frédéric Porte - Chairman of the Board, President, Medipress Management Inc. and Venture Partner, Genesys Capital Partner
Paul-Henry Schmelck, M.D. - Director, Investments, OTC Asset Management (France)
Jean-Paul St-Pierre, M.D. - Biotechnology Consultant and Practicing Physician
Philip S. Tabbiner, Ph.D. - President and General Manager, K-12 Learning and Development, Educational Testing System (USA)
Luc Tanguay - Executive Vice-President and Chief Financial Officer, Theratechnologies Inc.
Governance Documents